arrow
E

Edyta Zagórowicz

Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology
H指数:16
被引数:2,610

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Isolated perianal fistulizing Crohn’s disease in contemporary clinical practice: a multicenter ECCO-CONFER cohort study

孤立性肛周瘘管性克罗恩病在当代临床实践中的表现:一项多中心ECCO-CONFER队列研究

2026-09-110
OAAI
Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

波兰中重度溃疡性结肠炎或克罗恩病患者在 vedolizumab 诱导治疗期间的临床应答及生活质量、疲劳、情绪和睡眠障碍的改善

2026-06-020
OA
Building a Robust Investigator-Initiated Platform: The I-CARE Experience

构建一个稳健的 investigator-initiated 平台:I-CARE 经验

2026-02-150
OAAI
RESCUE-CD-Real-world effectiveness of risankizumab in moderate-to-severe Crohn's disease: a case series involving the most refractory and challenging patients

真实世界环境下鲁安克孜珠单抗治疗中重度克罗恩病的疗效:一项涉及最难治和最具挑战性患者的病例系列研究

2026-01-010
PRE
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study

炎症性肠病患者停用 vedolizumab 和 ustekinumab 后的复发率——一项多中心回顾性对照研究。VEDUST-EXIT 研究

2025-10-270
PRE
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

欧洲克罗恩结肠炎组织护理质量标准与欧洲IBD单位结构的现实世界之间的差距: 电子质量调查的结果

2025-07-012
PRE
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

Fiorino, G.; Fidalgo, C.; Adamina, M.; Barreiro-de Acosta, M.; Ali, M.P.; Bortlik, M.; Burisch, J.; Dignass, A.; Drobne, D.; Faiz, O.; 等. 欧洲克罗恩病与溃疡性结肠炎组织护理质量标准与实际诊疗在诊断和监测炎症性肠病方面的差距:欧洲E-QUALITY调查结果. J. Crohn’s Colitis 2025, 19, jjaf105. [Google Scholar] [CrossRef] [PubMed]

2025-07-011
PRE
Perianal Crohn's fistula in the absence of luminal disease -natural history, time to progression to luminal disease and management in contemporary clinical practice: An ECCO-CONFER case series
2025-01-220
PRE
Effectiveness of second-and-third line biologics in perianal Crohn's disease (pCD) - a multicenter propensity score-matched study
2025-01-220
PRE
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study
2025-01-220
PRE
Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II)
2024-11-200
OAAI
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
2023-03-0118
OAAI
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study
2023-02-142
OAAI
Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)
2021-08-306
OAAI
Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients
2019-10-1127
OAAI